KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nektar Therapeutics (NKTR) Prepaid Assets: 2010-2024

Historic Prepaid Assets for Nektar Therapeutics (NKTR) over the last 15 years, with Dec 2024 value amounting to $6.1 million.

  • Nektar Therapeutics' Prepaid Assets rose 24.81% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.1 million, marking a year-over-year increase of 24.81%. This contributed to the annual value of $6.1 million for FY2024, which is 37.97% down from last year.
  • Latest data reveals that Nektar Therapeutics reported Prepaid Assets of $6.1 million as of FY2024, which was down 37.97% from $9.8 million recorded in FY2023.
  • Over the past 5 years, Nektar Therapeutics' Prepaid Assets peaked at $23.3 million during FY2021, and registered a low of $6.1 million during FY2024.
  • In the last 3 years, Nektar Therapeutics' Prepaid Assets had a median value of $9.8 million in 2023 and averaged $10.6 million.
  • Its Prepaid Assets has fluctuated over the past 5 years, first skyrocketed by 42.51% in 2020, then slumped by 38.14% in 2023.
  • Over the past 5 years, Nektar Therapeutics' Prepaid Assets (Yearly) stood at $21.9 million in 2020, then rose by 6.41% to $23.3 million in 2021, then plummeted by 32.25% to $15.8 million in 2022, then crashed by 38.14% to $9.8 million in 2023, then plummeted by 37.97% to $6.1 million in 2024.